Glucagon-like peptide-1: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 22: Line 22:
==See also==
==See also==


* [[Glucagon-like peptide-1 analog]]
* [[Glucagon-like peptide 1 receptor]]
* [[Glucagon-like peptide 1 receptor]]
* [[Glucagon-like peptide-2]]
* [[Glucagon-like peptide-2]]

Revision as of 23:25, 6 March 2009

File:Incretins and DPP 4 inhibitors.svg
GLP-1 and DPP-4 inhibitors

WikiDoc Resources for Glucagon-like peptide-1

Articles

Most recent articles on Glucagon-like peptide-1

Most cited articles on Glucagon-like peptide-1

Review articles on Glucagon-like peptide-1

Articles on Glucagon-like peptide-1 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Glucagon-like peptide-1

Images of Glucagon-like peptide-1

Photos of Glucagon-like peptide-1

Podcasts & MP3s on Glucagon-like peptide-1

Videos on Glucagon-like peptide-1

Evidence Based Medicine

Cochrane Collaboration on Glucagon-like peptide-1

Bandolier on Glucagon-like peptide-1

TRIP on Glucagon-like peptide-1

Clinical Trials

Ongoing Trials on Glucagon-like peptide-1 at Clinical Trials.gov

Trial results on Glucagon-like peptide-1

Clinical Trials on Glucagon-like peptide-1 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Glucagon-like peptide-1

NICE Guidance on Glucagon-like peptide-1

NHS PRODIGY Guidance

FDA on Glucagon-like peptide-1

CDC on Glucagon-like peptide-1

Books

Books on Glucagon-like peptide-1

News

Glucagon-like peptide-1 in the news

Be alerted to news on Glucagon-like peptide-1

News trends on Glucagon-like peptide-1

Commentary

Blogs on Glucagon-like peptide-1

Definitions

Definitions of Glucagon-like peptide-1

Patient Resources / Community

Patient resources on Glucagon-like peptide-1

Discussion groups on Glucagon-like peptide-1

Patient Handouts on Glucagon-like peptide-1

Directions to Hospitals Treating Glucagon-like peptide-1

Risk calculators and risk factors for Glucagon-like peptide-1

Healthcare Provider Resources

Symptoms of Glucagon-like peptide-1

Causes & Risk Factors for Glucagon-like peptide-1

Diagnostic studies for Glucagon-like peptide-1

Treatment of Glucagon-like peptide-1

Continuing Medical Education (CME)

CME Programs on Glucagon-like peptide-1

International

Glucagon-like peptide-1 en Espanol

Glucagon-like peptide-1 en Francais

Business

Glucagon-like peptide-1 in the Marketplace

Patents on Glucagon-like peptide-1

Experimental / Informatics

List of terms related to Glucagon-like peptide-1

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Glucagon-like peptide-1 (GLP-1) is derived from the transcription product of the proglucagon gene. The major source of GLP-1 in the body is the intestinal L cell that secretes GLP-1 as a gut hormone. The biologically active forms of GLP-1 are: GLP-1-(7-37) and GLP-1-(7-36)NH2.

GLP-1 secretion by L cells is dependent on the presence of nutrients in the lumen of the small intestine. The secretagogues (agents that causes or stimulates secretion) of this hormone include major nutrients like carbohydrate, protein and lipid. Once in the circulation, GLP-1 has a half life of less than 2 minutes, due to rapid degradation by the enzyme dipeptidyl peptidase-4.

Physiological functions

GLP-1 possesses several physiological properties that make it a subject of intensive investigation as a potential treatment of diabetes mellitus.[1][2][3]. The known physiological functions of GLP-1 include:

See also

References

  1. "Diabetes and Intestinal Incretin Hormones: A New Therapeutic Paradigm" at medscape.com (slide 36)
  2. Toft-Nielsen M, Madsbad S, Holst J (2001). "Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes". J Clin Endocrinol Metab. 86 (8): 3853–60. PMID 11502823.
  3. Meier J, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck M, Holst J, Schmidt W, Gallwitz B (2004). "Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes". Crit Care Med. 32 (3): 848–51. PMID 15090972.

External links

Template:Proglucagon Template:Oral hypoglycemics Template:SIB

de:Glucagon-like Peptid 1


Template:WikiDoc Sources